Drugs / ETD001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07674862 | Mar → Jul 2026 overdue | — | Etern Therapeutics Wuxi Limited | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT04926701 | Jun 2021 → Mar 2022 | cystic fibrosis | Enterprise Therapeutics Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06478706 | Jun 2024 → Nov 2025 | cystic fibrosis | Enterprise Therapeutics Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETD001 | “Safety, Tolerability and Pharmacokinetics of ETD-001 Gel” NCT07674862 ↗ |
| Route | Inhaled | “Single ascending doses of inhaled ETD001” NCT04926701 ↗ |